The second biosimilar to infliximab (Remicade) is now available on the PBS. Marketed by MSD as Renflexis the biosimilar is approved in adults, for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, moderate to severe psoriasis and refractory fistulising Crohn’s disease. MSD Managing Director Riad El-Dada noted that the full potential of biosimilars had ...
Second infliximab biosimilar gets PBS listing
3 Aug 2017